Esperion to Report First Quarter 2026 Financial Results on May 7

About this update from Esperion Therapeutics, Inc.

ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website . Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. About Esperion Therapeutics   Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease. With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit  esperion.com  and follow Esperion on  LinkedIn  and  X . Esperion Contact Information: Investors: Alina Venezia [email protected] (734) 887-3903 Media: Tiffany Aldrich [email protected] (616) 443-8438

View stock analysis, news, and events for Esperion Therapeutics, Inc.